<PAGE>

                                                            EXHIBIT 10.16

                       FUSION MEDICAL TECHNOLOGIES, INC.

                     STOCK AND WARRANT PURCHASE AGREEMENT

     THIS STOCK AND WARRANT PURCHASE AGREEMENT is made as of the 2/nd/ day of
April 2001, by and between Fusion Medical Technologies, Inc. (the "Company"), a
corporation organized under the laws of the State of Delaware, with its
principal offices at 34175 Ardenwood Boulevard, Fremont, California 94555, and
the purchasers whose names and addresses are set forth on the signature page
hereof (individually a "Purchaser" and collectively the "Purchasers").

     IN CONSIDERATION of the mutual covenants contained in this Agreement, the
Company and the Purchaser agree as follows:

     1.   Authorization of Sale of the Securities. Subject to the terms and
          ---------------------------------------
conditions of this Agreement, the Company has authorized the sale of up to
3,500,000 shares of the Company's Common Stock, par value $0.001 per share (the
"Shares"). The Company has also authorized the issuance of warrants to purchase
900,000 shares of Common Stock (the "Warrant Shares") on the terms set forth
herein (each a "Warrant" and collectively the "Warrants"). The Shares, the
Warrants and the Warrant Shares are herein collectively referred to as the
"Securities".

     2.   Agreement to Sell and Purchase the Securities.
          ---------------------------------------------

          (a)  Execution Date. The "Execution Date" shall be the date each
               --------------
Purchaser signs this Agreement with the Company, whereupon the Company shall
agree to sell to the Purchaser, and the Purchaser shall agree to buy from the
Company, upon the terms and conditions hereinafter set forth, the number of
Shares and Warrants set forth opposite such Purchaser's name on Exhibit A
hereto.

          (b)  Calculation of the Purchase Price. The Shares will be sold to
               ---------------------------------
each Purchaser on Exhibit A at a price of $2.93 per share , which per share
price is the current market price of the Company's Common Stock calculated as
follows: the average of the daily closing stock prices for the Company's Common
Stock (ticker symbol "FSON") traded on the Nasdaq National Market for each of
the ten (10) trading days preceding the Execution Date of the Agreement (the
"Purchase Price").

          (c)  Calculation of the Warrants. The shares underlying each Warrant
               ---------------------------
as reflected on Exhibit A is calculated as follows: 25% of the aggregate
principal amount paid by the Purchaser divided by the Purchase Price. The
Warrant shall have an exercise price of $3.66, which is equal to 125% of the
Purchase Price. The Warrant shall be exercisable, in whole or in part until
April 2, 2006. The Warrant shall be in the form attached as Exhibit C hereto. No
fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant, but in lieu of such fractional shares the Company
shall make a cash payment therefor.

     3.   Delivery of the Shares and Warrants at the Closing
          --------------------------------------------------

               (i)  The distribution of the Shares and Warrants to be purchased
by the Purchasers (the "Closing") shall occur following the Execution Date on
April 2, 2001 following the Execution Date at the offices of Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304-1050 (the
"Closing Date").
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

               (ii) At the Closing, the Company shall deliver to the Purchaser
one or more stock certificates and a fully executed Warrant or Warrants to
purchase that number of shares of Common Stock as determined pursuant to Section
2.3 and as set forth in Exhibit A registered in the name of the Purchaser, or in
such nominee name(s) as designated by the Purchaser in writing, representing the
number of Securities set forth in Exhibit A. The name(s) in which the stock
certificates and Warrants are to be registered are set forth in the Stock
Certificate Questionnaire attached hereto as part of Appendix I. Prior to the
Purchaser's delivery of payment for the Securities, the Company shall deliver
via facsimile a copy of the stock certificate(s) and Warrants to be issued to
the Purchaser upon the Closing. The Company's obligation to complete the
purchase and sale of the Securities and deliver such stock certificate(s) and
warrant agreement to each Purchaser at the Closing shall be subject to the
following conditions: (i) receipt by the Company of same-day funds in the full
amount of the purchase price for the Securities being purchased hereunder; (ii)
completion of the purchase and sale with the other Purchasers; and (iii) the
accuracy of the representations and warranties made by the Purchaser as if made
on the day of such Closing and the fulfillment of those undertakings of the
Purchaser to be fulfilled prior to the Closing. The Purchaser's obligation to
accept delivery of such stock certificate(s) and Warrant(s) and to pay for the
Securities evidenced thereby shall be subject only to the following conditions:
(i) the accuracy in all material respects of the representations and warranties
made by the Company herein and the fulfillment in all material respects of those
undertakings of the Company to be fulfilled prior to Closing and (ii) the
delivery by Wilson Sonsini Goodrich & Rosati, counsel to the Company, to the
Purchaser of a legal opinion in substantially the form attached hereto as
Exhibit B.

     4.   Representations and Warranties of the Company. The Company hereby
          ---------------------------------------------
represents and warrants to each Purchaser as of the date hereof and as of the
Closing and except as set forth on a Schedule of Exceptions attached hereto as
Exhibit D, which exceptions shall be deemed to be representations and warranties
as if made hereunder as follows:

          (a)  Organization and Standing. The Company is a corporation duly
               -------------------------
organized and validly existing under the laws of the State of Delaware and is in
good standing under such laws. The Company has all requisite corporate power to
own and operate its properties and assets, and to carry on its business as
presently conducted. The Company is qualified to do business as a foreign
corporation in the State of California. Such qualification is not presently
required in any other jurisdiction where a failure to so qualify would have a
material adverse effect on the business, financial position or results of
operations of the Company ("Material Adverse Effect").

          (b)  Capitalization. The authorized capital stock of the Company
               --------------
consists of 50,000,000 shares of Common Stock and 5,000,000 shares of Preferred
Stock. A total of 11,285,626 shares of Common Stock are issued and outstanding.
No shares of Preferred Stock are issued and outstanding. All such issued and
outstanding shares have been duly authorized and validly issued, and are fully
paid and nonassessable. Options to purchase 2,992,569 shares of the Company's
Common Stock are outstanding under the Company's 1993 Stock Option Plan and
28,941 shares are available for future grant. Options to purchase 72,668 shares
of the Company's Common Stock are outstanding under the Company's 1996 Director
Option Plan and 44,800 shares are available for future grant. The Company has
issued 128,645 shares of Common Stock under its Employee Stock Purchase Plan and
151,355 shares are available for future issuance. The Company also has warrants
outstanding for 4,500 shares of its Common Stock. Except as disclosed in the
Company SEC Documents (as defined below), there are no other options, warrants,
conversion privileges, or preemptive or other rights or agreements presently
outstanding to purchase or otherwise acquire any authorized but unissued shares
of the capital stock or other securities of the Company.

                                      -2-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

          (c)  Authority.  The Company has full power and authority to execute
               ---------
and deliver this Agreement, and to consummate the transactions contemplated by
this Agreement. All corporate action on the part of the Company, its officers,
directors and stockholders necessary for the execution and delivery of, and the
consummation of the transactions contemplated by, this Agreement has been
obtained. This Agreement has been duly executed and delivered by the Company.
This Agreement, upon execution and delivery by the Company and assuming the due
and proper execution and delivery by the Purchaser, constitutes a legal, valid
and binding obligation of the Company, enforceable in accordance with its
respective terms, except as may be limited by (i) applicable bankruptcy,
insolvency, reorganization or other laws of general application relating to or
affecting the enforcement of creditors rights generally, and (ii) the effect of
rules of law governing the availability of specific performance and other
equitable remedies.

          (d)  Valid Issuance of the Securities. The Securities to be sold
               --------------------------------
hereby has been duly authorized and, when issued, delivered and paid for in the
manner set forth in this Agreement, shall be duly authorized, validly issued,
fully paid and nonassessable, and shall be free of restrictions on transfer
other than restrictions on transfer under this Agreement and under applicable
state and federal securities laws. No preemptive rights, anti-dilution rights or
other rights to subscribe for or purchase exist with respect to or will be
triggered by the issuance and sale of the Securities by the Company pursuant to
this Agreement. No stockholder of the Company has any right (which has not been
waived or has not expired by reason of lapse of time following the notification
of the Company's intent to file the Registration Statement (as defined in
Section 10.1) on the behalf of the Purchaser hereof to request or require the
Company to register the sale of any shares owned by such stockholder under the
Securities Act of 1933, as amended (the "Securities Act"), in the Registration
Statement.

          (e)  Governmental Consents. Other than compliance with the Securities
               ---------------------
Act and other state or federal securities laws, and such filings as may be
required to be made under such laws or with the National Association of
Securities Dealers (the "NASD"), which shall be complied with and made at or
prior to the Closing, no consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority on the part of the Company is
required in connection with the consummation of the transactions contemplated by
this Agreement.

          (f)  No Defaults/Conflicts. Except as to defaults, violations and
               ---------------------
breaches which individually or in the aggregate would not reasonably be expected
to have a Material Adverse Effect, the Company is not in violation or default of
any provision of its certificate of incorporation or bylaws of the Company or
any applicable statute, law, rule, regulation, ordinance, division, directive or
order, or in breach of or default with respect to any provision of any material
agreement, material covenant, material instrument, judgment, decree, order,
mortgage, loan agreement, deed of trust, note, lease, sublease, voting
agreement, voting trust, franchise, license, indenture, permit or other
instrument to which it is a party or by which it or any of its properties are
bound, or to which any of the property or assets of the Company are subject; and
there does not exist any state of facts which, with notice or lapse of time or
both, would constitute an event of default on the part of the Company as defined
in such documents, except such defaults which individually or in the aggregate
would not reasonably be expected to have a Material Adverse Effect.

          (g)  Contracts. The contracts that are material to the Company, are in
               ---------
full force and effect on the date hereof; and neither the Company nor, to the
Company's knowledge, any other party is in breach of or default under any of
such contracts which would reasonably be expected to have a Material Adverse
Effect.

                                      -3-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

          (h)  SEC Documents. The Company has filed each statement, annual,
               -------------
quarterly and other report, registration statement and definitive proxy
statement ("Company SEC Documents") required to be filed (other than preliminary
material) by the Company with the SEC. As of their respective filing dates, the
Company SEC Documents complied in all material respects with the requirements of
the Securities Act or the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), as the case may be, and none of the Company SEC Documents
contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements made
therein, in light of the circumstances in which they were made, not misleading,
except to the extent corrected by any subsequently filed Company SEC Document.

          (i)  Changes. Since September 30, 2000, (i) the Company has not
               -------
incurred any material liabilities or obligations, indirect, or contingent, or
entered into any material verbal or written agreement or other transaction which
is not in the ordinary course of business which could reasonably be expected to
have a Material Adverse Effect; (ii) the Company has not sustained any material
loss or interference with its businesses or properties from fire, flood,
windstorm, accident or other calamity not covered by insurance; (iii) the
Company has not paid or declared any dividends or other distributions with
respect to its capital stock and the Company is not in default in the payment of
principal or interest on any outstanding debt obligations; (iv) there has not
been any change in the capital stock of the Company other than the sale of the
Securities hereunder and shares or options issued pursuant to employee equity
incentive plans or purchase plans approved by the Company's Board of Directors,
or indebtedness material to the Company (other than in the ordinary course of
business); and (v) except for the operating losses and negative cash flow the
Company has continued to incur, there has not been a Material Adverse Change.

          (j)  Litigation. There are no other lawsuits, administrative
               ----------
proceedings, arbitrations, patent or licensing challenges or infringements,
labor disputes or governmental investigations to which the Company is a party or
by which any material portion of its assets, taken as a whole, may be bound,
which, if adversely determined, would have a Material Adverse Effect.

          (k)  Qualified Small Business Stock. The Company's Securities qualify
               ------------------------------
as "Qualified Small Business Stock" as defined in Section 1202 of the Internal
Revenue Code. The Company will comply with the reporting and record keeping
requirements of Section 1202 and will submit to its stockholders and to state
and federal taxation authorities such forms and filings as may be required to
document such compliance.

          (l)  Reservation of Warrant Shares. The Company agrees to keep
               -----------------------------
reserved from its authorized and unissued capital stock a sufficient number of
shares of Common Stock or other securities issuable upon exercise of the
Warrants to provide for the issuance of Common Stock or Warrant Shares.

          (m)  Compliance. The Company has conducted and is conducting its
               ----------
business in compliance with all applicable federal, state, local and foreign
statutes, laws, rules, regulations, ordinances, codes, decisions, decrees,
directives and orders, except where the failure to do so would not, singly or in
the aggregate, have a Material Adverse Effect on the condition, financial or
otherwise, or on the earnings, assets, business affairs or business prospects of
the Company.

          (n)  Intellectual Property. The Company owns or has obtained valid and
               ---------------------
enforceable licenses or options for all patents, patent applications,
inventions, trademarks, trade names, applications for registration of
trademarks, service marks, service mark applications, copyrights, know-how,
manufacturing processes, formulae, trade secrets, licenses and rights in any
thereof and any other intangible property and

                                      -4-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

assets that are material to the business of the Company as now conducted and as
proposed to be conducted (the "Intellectual Property") and to the Company's
knowledge (for each of the following subsections (a) through (e)): (a) there are
no third parties who have any ownership rights to any Intellectual Property that
is owned by, or has been licensed to, the Company that would preclude the
Company from conducting its business as currently conducted, except for the
ownership rights of the owners of the Intellectual Property licensed or optioned
by the Company; (b) there are currently no sales of any products that would
constitute an infringement by third parties of any Intellectual Property owned,
licensed or optioned by the Company; (c) there is no pending or threatened
action, suit, proceeding or claim by others challenging the rights of the
Company in or to any Intellectual Property owned, licensed or optioned by the
Company, other than claims which would not reasonably be expected to have a
Material Adverse Effect; (d) there is no pending or threatened action, suit,
proceeding or claim by others challenging the validity or scope of any
Intellectual Property owned, licensed or optioned by the Company, other than
claims which would not reasonably be expected to have a Material Adverse Effect;
and (e) there is no pending or threatened action, suit, proceeding or claim by
others that the Company infringes or otherwise violates any patent, trademark,
copyright, trade secret or other proprietary right of others, other than claims
which would not reasonably be expected to have a Material Adverse Effect, except
as described in the Schedule of Exceptions, Section 4.10.

          (o)  Properties. The Company has good and marketable title to all the
               ----------
properties and assets owned by it, subject to no lien, mortgage, pledge, charge
or encumbrance of any kind except (i) those, if any, reflected in the Company's
consolidated financial statements, or (ii) those which are not material in
amount and do not adversely affect the use made and intended to be made of such
property by the Company. The properties of the Company are, in the aggregate, in
good repair (reasonable wear and tear excepted) and suitable for their
respective uses. The Company holds its leased properties under valid and binding
leases, with such exceptions as would not reasonably be expected to have a
Material Adverse Effect. The Company owns or leases all such properties as are
necessary to its operations as now conducted.

          (p)  Taxes. The Company has filed all necessary federal, state and
               -----
foreign income and franchise tax returns and has paid or accrued all taxes shown
as due thereon, and the Company has no knowledge of a tax deficiency which has
been asserted or threatened against it except for such failures to file, or pay
or accrue or such deficiencies which would not reasonably be expected to have a
Material Adverse Effect.

          (q)  Transfer Taxes. On the Closing Date, all stock transfer or other
               --------------
taxes (other than income taxes) which are required to be paid in connection with
the sale and transfer of the Securities to be sold to the Purchaser hereunder
will be, or will have been, fully paid or provided for by the Company and all
laws imposing such taxes will be or will have been complied with in all material
respects.

          (r)  Insurance. The Company maintains insurance of the type and in the
               ---------
amount that the Company reasonably believes is adequate for its business,
including, but not limited to, insurance covering all real and personal property
owned or leased by the Company against theft, damage, destruction, acts of
vandalism and all other risks customarily insured against by similarly situated
companies, all of which insurance is in full force and effect in all material
respects.

          (s)  Additional Information. The Company represents and warrants that
               ----------------------
the information contained in the following documents (the "Company Documents'"),
which will be provided to Purchaser before the Closing, is or will be true and
correct in all material respects as of their respective final dates:

                                      -5-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

                         (1)  the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 1999;

                         (2)  the Company's Quarterly Reports on Form 10-Q for
the quarters ended June 30, 2000 and September 30, 2000;

                         (3)  the Company's Proxy Statement for its 2000 Annual
Meeting of Stockholders; and

                         (4)  all other documents, if any, filed by the Company
with the Commission since 1996 pursuant to the reporting requirements of the
Exchange Act.

               (t)  Use of Proceeds. The Company intends to use the proceeds
                    ---------------
from the sale of the Securities for working capital and other general corporate
purposes.

               (u)  Investment Company. The Company is not now, and after the
                    ------------------
sale of the Securities under this Agreement and under all other agreements and
the application of the net proceeds from the sale of the Securities described in
the preceding sentence will not be, an "investment company" or an "affiliated
person" of, or "promoter" or "principal underwriter" for an investment company
within the meaning of the Investment Company Act of 1940, as amended.

               (v)  Registration Exemption. Subject to the accuracy of the
                    ----------------------
Purchasers' representations and warranties in Section 5 of this Agreement, the
offer, sale, and issuance of the Securities in conformity with the terms of this
Agreement constitute transactions exempt from the registration requirements of
Section 5 of the Securities Act and from the registration or qualification
requirements of the laws of any applicable state or United States jurisdiction.

               (w)  No Integrated Offering. Neither the Company, nor any of its
                    ----------------------
affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales in any security or solicited any offers to
buy any security under circumstances that would require registration under the
Securities Act of the issuance of the Securities to the Purchasers. The issuance
of the Securities to the Purchasers will not be integrated with any other past
or current issuance of the Company's other securities for purposes of the
Securities Act or any applicable Nasdaq rules (or of any national securities
exchange on which the Company's Common Stock is then traded). The Company will
not make any offers or sales of any security (other than the Securities) that
would cause the offering of the Securities to be integrated with any other
offering of securities by the Company in violation of the Securities Act or any
applicable rules of the Nasdaq (or of any national securities exchange on which
the Company's Common Stock is then traded).

               (x)  Offering Materials. The Company has not distributed and will
                    ------------------
not distribute prior to the Closing Date any offering material in connection
with the offering and sale of the Securities other than material distributed to
the Purchasers. The Company has not in the past nor will it hereafter take any
action to sell, offer for sale or solicit offers to buy any securities of the
Company which would bring the offer, issuance or sale of the Securities, as
contemplated by this Agreement, within the provisions of Section 5 of the
Securities Act, unless such offer, issuance or sale was or shall be within the
exemptions of Section 4 of the Securities Act.

               (y)  No Manipulation of Stock. The Company has not taken and will
                    ------------------------
not, in violation of applicable law, take any action outside the ordinary course
of business designed to or that might reasonably

                                      -6-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

be expected to cause or result in unlawful manipulation of the price of the
Common Stock to facilitate the sale or resale of the Securities.

               (z)  Certificate. At the Closing, the Company will deliver to the
                    -----------
Purchaser a certificate executed by the Chairman of the Board or President and
the chief financial or accounting officer of the Company, dated the Closing
Date, in form and substance reasonably satisfactory to the Purchaser, to the
effect that the representations and warranties of the Company set forth in this
Section 4 are true and correct as of the date of this Agreement and as of the
Closing Date, and the Company has complied in all material respects with all the
agreements and satisfied all the conditions herein on its part to be performed
or satisfied on or prior to such Closing Date.

               (aa) Registration Rights. No stockholder of the Company has any
                    -------------------
right (which has not been waived or has not expired by reason of lapse of time
following notification of the Company's intent to file a registration statement
on behalf of the Purchaser pursuant to Section 10.1 hereof (the " Registration
Statement")) to require the Company to register the sale of any shares owned by
such stockholder under the Securities Act, in the Registration Statement.

               (bb) Legal Opinion. Upon the Closing, Wilson Sonsini Goodrich &
                    -------------
Rosati, counsel to the Company, will deliver its legal opinion to the Purchasers
in a form reasonably satisfactory to the Purchasers, their counsel and the
Company.

     5.   Representations and Warranties of the Purchaser. Each Purchaser hereby
          -----------------------------------------------
represents and warrants as of the date hereof and as of the Closing to the
Company as follows:

               (a)  Authority. The Purchaser has full power and authority to
                    ---------
execute and deliver, and to consummate the transactions contemplated by this
Agreement. All corporate action on the part of the Purchaser, its officers,
directors and stockholders necessary for the execution and delivery of, and the
consummation of the transactions contemplated by, this Agreement. This
Agreement, upon execution and delivery by the Purchaser and assuming the due and
proper execution and delivery by the Company, constitutes a legal, valid and
binding obligation of the Purchaser, enforceable in accordance with its terms,
except as may be limited by (i) applicable bankruptcy, insolvency,
reorganization or other laws of general application relating to or affecting the
enforcement of creditors rights generally, and (ii) the effect of rules of law
governing the availability of equitable remedies.

               (b)  Purchase Entirely for Own Account. This Agreement is made
                    ---------------------------------
with the Purchaser in reliance upon the Purchaser's representation to the
Company, which by the Purchaser's execution of this Agreement, the Purchaser
hereby confirms, that the Securities to be acquired by the Purchaser shall be
acquired for investment for the Purchaser's own account, not as a nominee or
agent, and not with a view to the distribution of any part thereof, and that the
Purchaser has no present intention of selling, granting any participation in, or
otherwise taking an action that would constitute a distribution of the same.

               (c)  Disclosure of Information. The Purchaser has received all
                    -------------------------
the information it considers necessary or appropriate for deciding whether to
purchase the Securities. The Purchaser further represents that it has had an
opportunity to ask questions and receive answers from the Company regarding the
terms and conditions of the offering of the Securities and the business,
properties, prospects and financial condition of the Company.

                                      -7-
<PAGE>

               (d)  Investment Experience. The Purchaser acknowledges that it is
                    ---------------------
able to fend for itself, can bear the economic risk of its investment, and has
such knowledge and experience in financial or business matters that it is
capable of evaluating the merits and risks of the investment in the Securities.
The Purchaser has not been organized for the purpose of acquiring the
Securities.

               (e)  Accredited Investor. The Purchaser is an "accredited
                    -------------------
investor" within the meaning of Rule 501 of Regulation D, promulgated under the
Securities Act.

               (f)  Restricted Securities. The Purchaser understands that the
                    ---------------------
Securities it is purchasing are characterized as "restricted securities" under
the federal securities laws inasmuch as they are being acquired from the Company
in a transaction not involving a public offering and that under such laws and
applicable regulations such securities may be resold without registration under
the Securities Act only in certain limited circumstances. In this connection,
the Purchaser represents that it is familiar with SEC Rule 144 or Rule 144A, as
presently in effect, and understands the resale limitations imposed thereby and
by the Securities Act.

     6.   Survival of Representations, Warranties and Agreements.
          ------------------------------------------------------
Notwithstanding any investigation made by any party to this Agreement, all
covenants, agreements, representations and warranties made by the Company and
the Purchaser herein shall survive until the three year anniversary of the
Closing.

     7.   Covenants of the Company.
          ------------------------

               (a)  Future Sales of Common Stock. In the event the Company
                    ----------------------------
shall, within ninety (90) days following the Closing Date, sell any shares of
the Company's Common Stock at, or any instruments (excluding the Company's 1993
Stock Option Plan, the 1996 Director Option Plan and the Employee Stock Purchase
Plan) that can be converted into or otherwise exchanged for the Company's Common
Stock (the "Subsequent Sale") exercisable at, a price per share (the "Subsequent
Purchase Price") of less than the Purchase Price, (1) the purchase price per
Share hereunder shall be adjusted to an amount equal to the Subsequent Purchase
Price, such that the Company shall, within ten (10) business days of the
Subsequent Sale, pay to each Purchaser an amount equal to the number of Shares
times the difference between the Purchase Price and the Subsequent Purchase
Price; and (2) the Company shall, within ten (10) business days of the
Subsequent Sale, deliver new Warrants to each Purchaser in exchange for the
previously issued Warrants that shall have an exercise price per share equal to
125% of the Subsequent Purchase Price.

               (b)  Listing of Shares. The Company agrees to promptly secure the
                    -----------------
listing of the Shares and Warrant Shares upon each national securities exchange
or automated quotation system upon which shares of Common Stock are then listed
for so long as any Purchaser owns any of the Shares or Warrant Shares. The
Company has taken no action designed to delist, or which is likely to have the
effect of delisting, the Common Stock from any of the national securities
exchange or automated quotation system upon which the shares of Common Stock are
then listed.

               (c)  Bylaw Amendment. The Company shall, within thirty (30) days
                    ---------------
of the Closing Date, adopt such amendments to, with respect to (i) and (ii)
below, the Company's stock option plans and Bylaws, and, with respect to (iii)
below, the Company's Bylaws (together, the "Stock Option Plan and Bylaw
Amendments") to provide that, unless approved by the holders of a majority of
the shares present and entitled to vote at a duly convened meeting of
shareholders, the company shall not (i) grant any stock options with an exercise
price that is less than 100% of the fair market value of the underlying stock on
the date of grant; (ii) reduce the exercise price of any stock option granted
under any existing or future stock option plan; or (iii)

                                      -8-
<PAGE>

sell or issue any security of the Company convertible, exercisable or
exchangeable into shares of Common Stock, having a conversion, exercise or
exchange price per share which is subject to downward adjustment based on the
market price of the Common Stock at the time of conversion, exercise or exchange
of such security into Common Stock (other than pursuant to customary anti-
dilution provisions). The Stock Option Plan and Bylaw amendments may not be
further amended or repealed without the affirmative vote of the holders of a
majority of the shares present and entitled to vote at a duly convened meeting
of shareholders. Upon the adoption of the Stock Option Plan and Bylaw
Amendments, the Company shall promptly furnish a copy of such amendments to the
Purchaser. The Company agrees that, prior to the adoption of the Stock Option
Plan and Bylaw Amendments by all necessary corporate action of the Company as
described above, the Company shall not conduct any of the actions specified in
(i), (ii) or (iii) above of this Section 7.3.

     8.   Covenants of the Purchaser.
          --------------------------

               (a)  Limitations on Disposition. Without in any way limiting any
                    --------------------------
other provision set forth herein, the Purchaser further agrees not to make any
disposition of all or any portion of the Securities unless and until:

                    (i)   There is then in effect a registration statement under
the Securities Act covering such proposed disposition and such disposition is
made in accordance with such Registration Statement;

                    (ii)  Such disposition shall be permitted under the
provisions of Rule 144; or

                    (iii) There is a valid exemption from registration under the
Securities Act and other applicable securities laws and, if requested by the
Company, the Purchaser shall have furnished the Company with an opinion of
counsel, reasonably satisfactory to the Company, that such disposition shall not
require registration.

          (b)  Prospectus Delivery. The Purchaser hereby covenants with the
               -------------------
Company not to make any sale of any Securities under a registration statement
without effectively causing the prospectus delivery requirement under the
Securities Act to be satisfied. The Purchaser acknowledges and agrees that such
Securities are not transferable on the books of the Company pursuant to a resale
under a registration statement unless the certificate submitted to the transfer
agent evidencing such Securities is accompanied by a separate officer's
certificate, (i) which may be in the form of Appendix II hereto, (ii) executed
by an officer of, or other authorized person designated by, the Purchaser, and
(iii) to the effect that (a) such Securities have been sold in accordance with
the registration statement and (b) the requirement of delivering a current
prospectus has been satisfied. The Purchaser acknowledges that there may
occasionally be times when the Company must suspend the use of the prospectus
forming a part of the registration statement until such time as an amendment to
the registration statement has been filed by the Company and declared effective
by the Securities and Exchange Commission (the "Commission"), or until such time
as the Company has filed an appropriate report with the Commission pursuant to
the Exchange Act. The Purchaser hereby covenants that it shall not sell any
Securities pursuant to such prospectus during the period commencing at the time
at which the Company gives the Purchaser prompt written notice of the suspension
of the use of such prospectus and ending at the time the Company gives the
Purchaser written notice that the Purchaser may thereafter effect sales pursuant
to such prospectus and any amendments thereto. In no event shall the Company
suspend the use of the prospectus for periods exceeding 30 days during any 12-
month period and any such suspension must be separated by a period of 30 days.

                                      -9-
<PAGE>

     9.   Legends. Each certificate or instrument representing Securities
          -------
delivered at the Closing shall bear legends in substantially the following
forms:

                    (1)  "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE `SECURITIES ACT') AND
ARE `RESTRICTED SECURITIES' AS DEFINED IN RULE 144 PROMULGATED UNDER THE
SECURITIES ACT. THE SECURITIES MAY NOT BE SOLD OR OFFERED FOR SALE OR OTHERWISE
DISTRIBUTED EXCEPT (I) IN CONJUNCTION WITH AN EFFECTIVE REGISTRATION STATEMENT
FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (II) IN COMPLIANCE WITH RULE
144, OR (III) PURSUANT TO AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF
THESE SECURITIES THAT SUCH REGISTRATION OR COMPLIANCE IS NOT REQUIRED AS TO SUCH
SALE, OFFER OR DISTRIBUTION."

                    (2)  Any other legends required by California law or other
applicable blue sky or state securities laws.

The Company need not register a transfer of any Securities, and may also
instruct its transfer agent not to register a transfer of any Securities, unless
the conditions specified in the foregoing legends are satisfied to the extent
applicable.

     10.  Registration of the Securities; Compliance with the Securities Act.
          ------------------------------------------------------------------

               (a)  Registration Procedures and Expenses. The Company shall:
                    ------------------------------------

                         (i)   within 30 business days after the Closing Date,
prepare and file with the Commission a registration statement on Form S-3 (the
"Registration Statement") relating to the sale of the Securities by the
Purchaser on the Nasdaq National Market or the facilities of any national
exchange on which the Common Stock is then traded or in privately-negotiated
transactions;

                         (ii)  shall respond to all Commission comments within
ten (10) calendar days of receipt of said comments and will use its best
efforts, subject to receipt of necessary information from the Purchasers, to
cause the Commission to notify the Company of the Commission's willingness to
grant acceleration of the effective date of the Registration Statement within 90
days after the Registration Statement is initially filed by the Company;

                         (iii) promptly notify the Purchaser upon the
Registration Statement being declared effective by the Commission;

                         (iv)  provide to the Purchaser any information
necessary to permit sale of the Securities under Rule 144 or Rule 144A of the
Securities Act.

                         (v)   prepare and file with the Commission such
amendments and supplements to the Registration Statement and the prospectus used
in connection therewith as may be necessary to keep the Registration Statement
effective until the date on which the Purchaser's Securities may be resold in
any three-month period by the Purchaser without registration and without any
restrictions or volume limitations by reason of Rule 144(k) under the Securities
Act or any other rule of similar effect;

                                      -10-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

                 (vi)    promptly furnish to the Purchaser with respect to the
Securities registered under the Registration Statement (and to each underwriter,
if any, of such Securities) such number of copies of prospectuses and such other
documents as the Purchaser may reasonably request, in order to facilitate the
public sale or other disposition of all or any of the Purchaser's Securities by
the Purchaser; provided, however, that the obligation of the Company to deliver
copies of prospectuses to the Purchaser shall be subject to the receipt by the
Company of reasonable assurances from the Purchaser that the Purchaser shall
comply with the applicable provisions of the Securities Act and of such other
securities or blue sky laws as may be applicable in connection with any use of
such prospectuses;

                 (vii)   file documents required of the Company for normal blue
sky clearance in all states requiring blue sky clearance; provided, however,
that the Company shall not be required to qualify to do business or consent to
service of process in any jurisdiction in which it is not now so qualified or
has not so consented unless failing to so qualify or consent has a Material
Adverse Effect on the Company; and

                 (viii)  bear all expenses in connection with the procedures in
paragraphs (a) through (g) of this Section 10.1 and the registration of the
Securities pursuant to the Registration Statement, other than underwriting
discounts, brokerage fees and commissions incurred by the Purchaser, if any.

          (b) Delay in Effectiveness of Registration Statement. In the event
              ------------------------------------------------
that the Registration Statement is not declared effective on or before the 90th
day following the Closing Date (the "Penalty Date"), the Company shall pay to
each Purchaser liquidated damages in an amount equal to 0.25% of the total
purchase price of the Securities purchased by such Purchaser pursuant to this
Agreement for each week after the Penalty Date that the Registration Statement
is not declared effective.

          (c) Transfer of Securities After Registration. The Purchaser agrees
              -----------------------------------------
that it shall not effect any disposition of any Securities or its right to
purchase any Securities that would constitute a sale within the meaning of the
Securities Act, except as contemplated in the Registration Statement referred to
in Section 10.1 or as otherwise permitted by law, and that it shall promptly
notify the Company of any changes in the information set forth in the
Registration Statement regarding the Purchaser or its plan of distribution.

          (d) Indemnification. In the event any securities are included in a
              ---------------
registration statement under this Section 10:

                 (i)     To the extent permitted by law, the Company shall
indemnify and hold harmless the Purchaser and each person, if any, who controls
the Purchaser within the meaning of the Securities Act or the Exchange Act,
against any losses, claims, damages, or liabilities (joint or several) to which
they may become subject under the Securities Act or the Exchange Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities
(or actions in respect thereof) arise out of or are based upon any of the
following statements, omissions or violations (collectively a "Violation"): (i)
any untrue statement or alleged untrue statement of a material fact contained in
such Registration Statement, including any preliminary prospectus or final
prospectus contained therein or any amendments or supplements thereto, (ii) the
omission or alleged omission to state therein a material fact required to be
stated therein, or necessary to make the statements therein not misleading, or
(iii) in connection with the sale or purchase of the Securities, any violation
or alleged violation by the Company of the Securities Act, the Exchange Act, any
state securities law or any rule or regulation promulgated under the Securities
Act, or the Exchange Act or any state securities law; and the Company shall pay
to the Purchaser or controlling person, as incurred, any legal or other expenses
reasonably incurred by them in connection with investigating or defending any
such loss,

                                      -11-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

claim, damage, liability, or action; provided, however, that the indemnity
agreement contained in this subsection 10.4(a) shall not apply to amounts paid
in settlement of any such loss, claim, damage, liability, or action if such
settlement is effected without the consent of the Company (which consent shall
not be unreasonably withheld), nor shall the Company be liable in any such case
for any such loss, claim, damage, liability, or action to the extent that it
arises out of or is based upon a Violation which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection
with such registration by the Purchaser or controlling person.

                 (ii)    To the extent permitted by law, the Purchaser shall
indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each person, if any, who
controls the Company within the meaning of the Securities Act, its attorneys,
its underwriters, and any controlling person of any such underwriter, against
any losses, claims, damages, or liabilities (joint or several) to which any of
the foregoing persons may become subject, under the Securities Act, or the
Exchange Act or other federal or state law, insofar as such losses, claims,
damages, or liabilities (or actions in respect thereto) arise out of or are
based upon any Violation, in each case to the extent (and only to the extent)
that such Violation occurs in reliance upon and in conformity with written
information furnished by the Purchaser expressly for use in connection with such
registration; and the Purchaser shall pay, as incurred, any legal or other
expenses reasonably incurred by any person intended to be indemnified pursuant
to this subsection 10.4(b), in connection with investigating or defending any
such loss, claim, damage, liability, or action; provided, however, that the
indemnity agreement contained in this subsection 10.4(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action
if such settlement is effected without the consent of the Purchaser, which
consent shall not be unreasonably withheld; provided, that, in no event shall
any indemnity under this subsection 10.4(b) exceed the gross proceeds from the
offering received by the Purchaser.

                 (iii)   Promptly after receipt by an indemnified party under
this Section 10.4 of notice of the commencement of any action (including any
governmental action), such indemnified party shall, if a claim in respect
thereof is to be made against any indemnifying party under this Section 10.4,
deliver to the indemnifying party a written notice of the commencement thereof
and the indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this Section
10.4, but the omission so to deliver written notice to the indemnifying party
shall not relieve it of any liability that it may have to any indemnified party
otherwise than under this Section 10.4.

                 (iv)    If the indemnification provided for in this Section
10.4 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage, or expense
referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such loss, liability, claim, damage, or
expense in such proportion as is appropriate to reflect the relative fault of
the

                                      -12-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such loss,
liability, claim, damage, or expense as well as any other relevant equitable
considerations; provided that in no event shall any contribution by the
                --------
Purchaser under this subsection 10.3(d) exceed the amount of the gross proceeds
received by the Purchaser from the offering. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission to state a material fact relates to information
supplied by the indemnifying party or by the indemnified party and the parties'
relative intent, knowledge, access to information, and opportunity to correct or
prevent such statement or omission.

                 (v)     The obligations of the Company and the Purchaser under
this Section 10.4 shall survive the completion of any offering of securities in
a registration statement under this Section 10.4 or otherwise.

          (e) Termination of Registration Obligations. The obligations of the
              ---------------------------------------
Company set forth in Section 10.1 shall cease and terminate as to the
Purchaser's Securities on the date on which (i) all such Securities are eligible
for sale during any three-month period without restriction including volume
limitations, under Rule 144, (ii) all such Securities have been effectively
registered under the Securities Act and sold or otherwise disposed of by the
Purchaser in accordance with the intended method of disposition set forth in the
Registration Statement or (iii) the Company receives an opinion of counsel
satisfactory in form and substance to the Company to the effect that such
conditions are not necessary in order for a transfer of such Securities to
comply with the Securities Act.

          (f) Information Available. So long as the Registration Statement is
              ---------------------
effective covering the resale of Securities owned by the Purchaser, the Company
shall furnish to the Purchaser:

                 (i)     as soon as practicable after the Company has made such
information available to the public through submission to the SEC (but in the
case of the Company's Annual Report to Stockholders, within 120 days after the
end of each fiscal year of the Company), one copy of (i) its Annual Report to
Stockholders, (ii) if not included in substance in the Annual Report to
Stockholders, its Annual Report on Form 10-K, (iii) its Quarterly Reports on
Form 10-Q, (iv) its Current Reports on Form 8-K, and (v) a full copy of the
particular Registration Statement covering the Securities (the foregoing, in
each case, excluding exhibits); and

                 (ii)    upon the written request of the Purchaser, a reasonable
number of copies of the prospectuses to supply to any other party requiring such
prospectuses in connection with the Purchaser's prospectus delivery requirements
under the Securities Act; and

                 (iii)   the Company, upon the reasonable request of the
Purchaser, shall meet with the Purchaser or a representative thereof at the
Company's headquarters to discuss information relevant for disclosure in the
Registration Statement covering the Securities, subject to appropriate
confidentiality limitations as the Company may require.

     11. Rule 144 Information. For two years after the date of this Agreement,
         --------------------
the Company shall file all reports required to be filed by it under the
Securities Act, and the Exchange Act and shall take such further action to the
extent required to enable the Purchasers to sell the Securities pursuant to Rule
144 under the Securities Act (as such rule may be amended from time to time).

                                      -13-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

     12. Brokers. Each of the parties hereto hereby represents that, on the
         -------
basis of any actions and agreements by it, there are no brokers or finders
entitled to compensation in connection with the sale of the Securities to the
Purchaser.

     13. Notices. All notices, requests, consents and other communications
         -------
hereunder shall be in writing, shall be mailed by first-class registered or
certified airmail, confirmed facsimile or nationally recognized overnight
express courier postage prepaid, and shall be deemed given when so mailed and
shall be delivered as addressed as follows:

                 (i)     if to the Company, to:

                         Fusion Medical Technologies, Inc.
                         34175 Ardenwood Boulevard
                         Fremont, California 94555
                         Attention: Larry J. Strauss
                         Facsimile: (510) 818-4700

                         with a copy to:

                         Wilson Sonsini Goodrich & Rosati
                         650 Page Mill Road
                         Palo Alto, CA 94304-1050
                         Attention: Charles Szurgot
                         Facsimile: (650) 565-3900

         or to such other person at such other place as the Company shall
designate to the Purchaser in writing; and

                 (ii)    if to the Purchaser, at its address as set forth at the
end of this Agreement, or at such other address or addresses as may have been
furnished to the Company in writing.

     14. Changes. This Agreement may not be modified or amended except pursuant
         -------
to an instrument in writing signed by the Company and the Purchaser.

     15. Expenses. The Company will pay the cost to prepare and file all
         --------
documents, including the necessary registration documents. At the Closing, the
Company will pay reasonable legal fees, not to exceed $25,000, to Alloy
Ventures, including fees to prepare and file the necessary Form 3, Form 4 and
initial Section 13D or 13G filings. At the Closing, the Company will also pay a
flat fee of $7,500, to State of Wisconsin Investment Board for their legal
expenses whether (internal or external) arising in connection with the
transactions contemplated by this Agreement.

     16. Headings. The headings of the various sections of this Agreement have
         --------
been inserted for convenience of reference only and shall not be deemed to be
part of this Agreement.

     17. Severability. In case any provision contained in this Agreement should
         ------------
be invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein shall not in any way
be affected or impaired thereby.

                                      -14-
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

     18. Governing Law. This Agreement shall be governed by and construed in
         -------------
accordance with the laws of the State of California.

     19. No Conflicts of Interest. The Company represents, warrants, and
         ------------------------
covenants that, to the best of its knowledge, no trustee or employee of the
State of Wisconsin Investment Board identified on Exhibit E, either directly or
indirectly (a) currently holds, except as may be specifically set forth below, a
personal interest in the Company or any of its affiliates (together, the
"Entity") or the Entity's property or securities, or (b) will, in connection
with the investment made pursuant to this Agreement, receive (i) a personal
interest in the Entity or the Entity's property or securities or (ii) anything
of substantial economic value for his or her private benefit from the Entity or
anyone acting on its behalf. As to ownership of an interest in the Entity's
publicly traded securities, "knowledge" hereunder is based on an examination of
record holders of the Entity's securities and actual knowledge of the
undersigned.

     20. Counterparts. This Agreement may be executed in two or more
         ------------
counterparts, each of which shall constitute an original, but all of which, when
taken together, shall constitute but one instrument, and shall become effective
when one or more counterparts have been signed by each party hereto and
delivered to the other parties.

                                      -15-
<PAGE>

     IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement
or caused this Agreement to be executed by its duly authorized representative as
of the day and year first above written.

                                    FUSION MEDICAL TECHNOLOGIES, INC.

                                    By_________________________________
                                       Name: Larry J. Strauss
                                       Title:  Vice President of Finance & Chief
                                       Financial Officer
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT


Print or Type:                      Name of the Purchaser
                                    (Individual or Institution):

                                    _________________________________
                                    Name of Individual representing
                                       the Purchaser (if an Institution):

                                    _________________________________
                                    Title of Individual representing
                                       the Purchaser (if an Institution):

                                    _________________________________

Signature by:                       Individual Purchaser or Individual
                                       representing the Purchaser:

                                    _____________________________________

                                    Address:  ___________________________

                                    Telephone:  ___________________________

                                    Facsimile:  ___________________________
<PAGE>

                                  Appendix I
                               (page one of two)

FUSION MEDICAL TECHNOLOGIES, INC.

STOCK CERTIFICATE QUESTIONNAIRE
-------------------------------

     Pursuant to Section 3 of the Agreement, please provide us with the
following information:

     1.  The exact name in which your Securities
are to be registered (this is the name that shall
appear on your stock certificate(s)); you may use
a nominee name if appropriate:                        __________________________

     2.  The relationship between the Purchaser of
the Securities and the Registered Holder listed in
response to item 1 above:                             __________________________

     3.  The mailing address of the Registered
Holder listed in response to item 1 above:            __________________________

                                                      __________________________

                                                      __________________________

                                                      __________________________

     4.  The Social Security Number or Tax
Identification Number of the Registered Holder
listed in response to item 1 above:                   __________________________

<PAGE>

                                   Appendix I
                               (page two of two)

                       FUSION MEDICAL TECHNOLOGIES, INC.

                      REGISTRATION STATEMENT QUESTIONNAIRE
                      ------------------------------------

     In connection with the preparation of the Registration Statement, please
provide us with the following information:

     1.  Pursuant to the "Selling Stockholder" section of the Registration
         Statement, please state your or your organization's name exactly as it
         should appear in the Registration Statement:

     ---------------------------------------------------------------------------

     2.  Please provide the number of shares that you shall beneficially own
         immediately after Closing, including those Securities purchased by you
         pursuant to the Agreement and those shares purchased by you or your
         affiliates through other transactions:

     ---------------------------------------------------------------------------

     3.  Have you or your organization had any position, office or other
material relationship within the past three years with the Company or its
affiliates?

            _____ Yes       _____ No

         If yes, please indicate the nature of any such relationships below:

         _________________________________________________________________

         _________________________________________________________________

         _________________________________________________________________
<PAGE>

                                  Appendix II

Attention:

                   PURCHASER'S CERTIFICATE OF SUBSEQUENT SALE
                   ------------------------------------------
                      PURSUANT TO A REGISTRATION STATEMENT
                      ------------------------------------

     The undersigned, [an officer of, or other person duly authorized by]

________________________________________________________________________________
             [fill in official name of individual or institution]

hereby certifies that he/she [said institution] is the Purchaser of

the shares evidenced by the attached certificate, and as such,

sold such shares on ____________ in accordance with
                       [date]

Registration Statement number ________________ and the requirement of delivering

     [fill in the number of or otherwise identify Registration Statement]

a current prospectus by the Company has been complied with in connection with
such sale.

Print or Type:

     Name of the Purchaser
     (Individual or
     Institution):       ______________________

     Name of Individual
     representing the
     Purchaser (if an
     Institution)         ______________________

     Title of Individual
     representing the
     Purchaser (if an
     Institution):        ______________________

Signature by:

     Individual Purchaser
     or Individual
     representing the Purchaser:   ______________________


<PAGE>

                                   EXHIBIT A

                             SCHEDULE OF PURCHASERS

<TABLE>
<CAPTION>
                                                          Investment        No. of Shares of       No. of Shares
            Name and Address                                Amount            Common Stock      Subject to Warrant
 -----------------------------------------------------    ----------        ----------------    ------------------
<S>                                                       <C>                  <C>                  <C>
Alloy Ventures 2000, LLC                                  $6,000,000            2,047,781              511,945

State of Wisconsin Investment Board I                     $  960,000              327,645               81,911

State of Wisconsin Investment Board II                    $  240,000               81,911               20,478

Asset Management, LLC                                     $  800,000              273,038               68,259

TOTAL                                                     $8,000,000            2,730,375              682,593
                                                          ==========            ---------              =======
</TABLE>
<PAGE>

                                   EXHIBIT B

                                FORM OF OPINION
                                       OF
                        WILSON SONSINI GOODRICH & ROSATI


<PAGE>

                                   EXHIBIT C

                                    WARRANT
<PAGE>

STOCK AND WARRANT PURCHASE AGREEMENT

                                   EXHIBIT D

                             SCHEDULE OF EXCEPTIONS

     This Schedule of Exceptions, is made pursuant to Section 4 of the Fusion
Medical Technologies, Inc.'s (the "Company") Stock and Warrant Purchase
Agreement (the "Agreement").  The section numbers in this Schedule of Exceptions
correspond to the section numbers in the Agreement; however, any information
disclosed herein under any section number shall be deemed to be disclosed and
incorporated into any other paragraph number under the Agreement where such
disclosure would be appropriate.  Any terms defined in the Agreement shall have
the same meaning when used in this Schedule of Exceptions as when used in the
Agreement unless the context otherwise requires.

     Section 4.2   Capitalization.  The Company has a Preferred Shares Rights
                   --------------
Agreement dated as of October 10, 1997, as amended on March 30, 1999 (the
"Rights Agreement") which provides registered holders of the Company's Common
Stock the right to purchase 1/1000th share of the Company's Series A
Participating Preferred Stock for each share of Common Stock then held (the
"Rights").  The Rights separate from the Common Shares and Rights Certificates
are issued and the Rights become exercisable upon 10 days (or such later date as
may be determined by a majority of the Board of Directors, excluding directors
affiliated with the Acquiring Person), following a public announcement that a
person or a group of affiliated or associated persons has acquired, or obtained
the right to acquire, beneficial ownership of 15% or more of the outstanding
Common Shares (the "Distribution Date").  On April 2, 2001, the representations
and warranties made to each Purchaser by the Company failed to disclose the
existence of the Rights Agreement and the need to amend the Rights Agreement in
order to avoid Alloy Ventures ("Alloy") and the State of Wisconsin Investment
Board ("SWIB") falling within the definition of an "Acquiring Person"
thereunder.  The Board of Directors has approved an amendment to the Rights
Agreement. The Company will prepare and file an amendment to the Rights
Agreement on or before April 12, 2001 to increase from 15% to 20% the
designation of "Acquiring Person" for Alloy and SWIB.

     Section 4.4   Valid Issuance of the Securities.  The Company has an
                   --------------------------------
outstanding warrant (the "Warrant") currently exercisable into 4,500 Common
Stock shares of the Company.  After completion of the Agreement, the Warrant
will be exercisable into 6,000 Common Stock shares due to the anti-dilution
provision contained in the Warrant.

     Section 4.10  Litigation.  On December 19, 2000, Cohesion Technologies,
                   ----------
Inc. filed a patent infringement action against the Company in United States
District Court, Northern District of California (San Jose) claiming that the
Company infringed on Cohesion Technologies' "Collagen-Polymer Matrices With
Differential Biodegradability" patent (Patent #6,110,484). Cohesion Technologies
is seeking unspecified damages and permanent injunctive relief. The Company
believes that Cohesion Technologies' claim is without merit.
<PAGE>

                                   EXHIBIT E


              TRUSTEES OF THE STATE OF WISCONSIN INVESTMENT BOARD


Jon D. Hammes                      George H. Hahner
John Petersen III                  George F. Lightbourn
Eric O. Stanchfield                James R. Nelsen
Andrea Steen Crawford              William R. Sauey
James A. Senty

         RELEVANT EMPLOYEES OF THE STATE OF WISCONSIN INVESTMENT BOARD

All Transactions
----------------
Patricia Lipton          Executive Director
Joseph Gorman            Chief Investment Officer - Equities
Keith Johnson            Chief Legal Counsel
Teresa Lau               Assistant Legal Counsel
Cynthia Richson          Assistant Legal Counsel
Jon Traver               Chief Investment Officer - Fixed Income

For Real Estate Transactions
----------------------------
Robert Severance         Investment Director
Chuck Carpenter          Assistant Investment Director
Dave Lewandowski         Investment Officer
Steve Spiekerman         Investment Officer

For Private Placement Loans
---------------------------
Jim Gannon               Investment Director
Eve Hennessee            Portfolio Manager
Monica Jaehnig           Portfolio Manager
Chris Prestigiacomo      Investment Officer
Mary Micheels            Investment Officer

For Private Placement Funds & Equity Investments
------------------------------------------------
Jim Gannon               Investment Director
Jon Vanderploeg          Portfolio Manager
Carrie Thome             Assistant Portfolio Manager
Tom Olson                Investment Officer

For Non-traditional Investments
-------------------------------
Mike Wagner              Investment Director
George Semka             Assistant Portfolio Manager
Tom Drake                Securities Analyst

For Small Cap Portfolio Direct Placements
-----------------------------------------
John Nelson              Investment Director
Chad Neumann             Assistant Portfolio Manager
Mark Traster             Securities Analyst
Jackie Doeler            Securities Analyst
Dan Kane                 Securities Analyst